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   A 40 year old African Amercian male, with a history of diabetes, presented to the emergency department with 
persistent diarrhea over the past few months.  Soon after arrival, the patient developed respiratory failure, requir-
ing mechanical ventilation.  Labs at the time of presentation revealed severe hypokalemia (K 1.0), metabolic aci-
dosis (HCO3 10), prerenal azotemia (BUN 150, Cr 11) and marked hypoalbuminemia (Alb 1.0).  IV hydration and 
electrolyte supplementation were initiated, he was soon extubated and he had a relatively uneventful hospital 
course.  A non-contrast CT of the abdomen was normal and a colonic biopsy showed only nonspecific, mild in-
flammation. 
   Two weeks after discharge, the patient presented with worsening diarrhea (up to 40 times per day) and severe 
weakness; he denied hematochezia or melena and had no abdominal pain.  His past medical history was remark-
able for diabetes mellitus, hypertension, a seizure disorder (thought to be related to alcohol use) and a long his-
tory of alcohol and tobacco abuse.  Surgical history was limited to amputation of a toe due to gangrene.  He ad-
mitted to noncompliance regarding his medications.  Family history was also positive for hypertension and dia-
betes. 
   His admission exam revealed that he was alert and oriented to time, person and place.  He was pale and his 
mucous membranes were dry.  Orthostatic vitals revealed a BP of 132/97 and P 81 when supine, BP 87/45 and P 
115 when standing.  Chest was clear to auscultation.  Abdomen was soft, non-tender and non-distended; bowel 
sounds were diffusely hyperactive.  Skin turgor was decreased, generalized muscular weakness was noted but no 
neurologic deficits were found. 
   Admission labs revealed WBC 13,300 (with 63.5%N, 29.6%L, 1%Eos, 5%M), Hgb 7.8, Hct 22,  and platelet count 
of 213,000.  Chemistries returned Na 136, K 1.7, Cl 115, HCO3 14, BUN 12, Cr 2.4, Gluc 153, Ca 6.1, Alb 2.6, AST 
65, ALT 34 and AlkPhos 168.  His serum amylase and lipase were normal.  EKG demonstrated T wave inversion 
and U waves, reflecting his severe hypokalemia.  A CXR was normal and plain abdominal films were unremark-
able. 
   IV hydration and electrolyte repletion were initiated.  Based on the conviction that this patient may have 
chronic pancreatic insufficiency, he was started on pancreatic enzyme supplementation.  His electrolye abnor-
malities and diarrhea soon resolved and he was doing well at the time of followup, 1 month later; he did report 
that his diarrhea would redevelop if he stopped taking the enzyme supplements for a few days.  At a followup 
visit 2 years later, the patient has remained compliant with his medications and has had no further diarrhea. 
 
Discussion:   Pancreatic insufficiency usually causes severe protein and fat malabsorption; patients generally be-
come symptomatic once 90% of the pancreatic exocrine function has been lost.  One of the most common causes 
of pancreatic insufficiency is chronic pancreatitis, usually secondary to a long history of alcohol abuse. 
Chronic pancreatitis is a syndrome that involves progressive inflammatory change in the pancreas, eventually 
resulting in permanent structural damage; this leads to impairment of endocrine and exocrine function.  Patients 
with chronic pancreatitis often complain of epigastric pain (which may radiate to the back), weight loss and diar-
rhea; nausea and vomiting may also occur.  Our patient, though plagued by severe diarrhea, did not experience 
abdominal pain; in one study, 20% of patients with chronic pancreatitis presented with endocrine or exocrine 
dysfunction in the absence of abdominal pain.  Forty five percent of asymptomatic alcoholics have been found to 
have evidence of chronic pancreatitis on postmortem examination [1]. 
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Rise  The true prevalence of chronic pancreatitis is not known, although estimates range from .04 to 5 percent [2].  A 
long history of heavy alcohol consumption (at least 6-12 years) accounts for 60-70% of cases in developed coun-
tries [3].  Obstruction of the pancreatic duct can also lead to chronic pancreatitis; this is characterized by dilation 
of the pancreatic duct and exocrine insufficiency.  Tropical pancreatitis, most often seen in Africa and Asia, ap-
pears in young persons and is characterized by pancreatic insufficiency, diabetes mellitus and recurrent abdomi-
nal pain; it is uncertain whether this condition is caused by protein malnutrition or by ingestion of toxic sub-
stances such as the cyanogens in cassava root [4].  Mutations in serine protease inhibitor SPINK1 have been iden-
tified as a cause in some patients [5-6].  Chronic pancreatitis can also occur in association with cystic fibrosis or 
hyperparathyroidism [3]. 
Autoimmune pancreatitis is most often seen in the Far East and is associated with other autoimmune disorders 
such as Sjogren’s syndrome and SLE; these patients have autoantibodies such as ANA and increased gamma 
globulin in their blood and often have no or minimal symptoms [7].  Approximately 30-40% of patients with 
chronic pancreatitis have no apparent underlying cause and are thus classified as idiopathic chronic pancreatitis.  
Regardless of the cause, the pathogenesis of chronic pancreatitis, though poorly understood, has been attributed 
to an increased secretion of ductal protein without a compensatory increase in ductal bicarbonate; histologic ex-
amination may reveal patchy inflammatory changes within the exocrine pancreas. 
Diagnostic Considerations.  An accurate history and diagnostic evaluation is required to confirm the presence of 
chronic pancreatitis.  Steatorrhea  may be assessed qualitatively by looking for fat globules or by staining stool 
samples with Sudan red; quantitative results are obtained by fecal fat excretion (>20 grams per 24 hours).  Dy-
namic testing, such as the secretin stimulation test and the bentiromide (chymex) test, and quantitative tests such 
as stool chymotrypsin are now infrequently used due to a significant improvement in imaging technology [8].  
Diffuse, intraductal calcium deposition, pathognomonic of chronic pancreatitis, will be seen on plain abdominal 
radiographs in up to 30% of cases [9].  The diagnostic sensitivity and specificity of ultrasound is 60-70% and 80-
90% respectively [10].  CT scanning has a higher sensitivity and is the imaging modality of choice to look for com-
plications of chronic pancreatitis [11].  Endoscopic ultrasonography is becoming a popular tool for the diagnosis 
and ERCP remains the gold standard for confirming chronic pancreatitis secondary to ductal abnormalities [12]. 
When the diagnosis remains uncertain, other causes of chronic abdominal pain, such as peptic ulcer disease, gall-
stones, irritable bowel syndrome and endometriosis, should be considered.  The possibility of pancreatic carci-
noma must be kept in mind since it can mimic chronic pancreatitis and may develop against the background of 
pancreatitis, often delaying the diagnosis until late in the disease process [8]. 
 
Treatment Considerations.  The treatment of chronic pancreatitis involves the elimination of its cause, sympto-
matic therapy and pancreatic enzyme supplementation.  Cessation of alcohol is imperative; while this may or 
may not relieve pain, it does reduce mortality [2].  Dietary changes, especially the consumption of small meals 
with low fat content, often improves symptoms; pancreatic enzyme supplementation may also reduce pain in 
some patients [13].  Oral trypsin deactivates intrinsic cholecystokinin and thus decreases pancreatic stimulation 
of digestive peptides; this appears to be the mechanism by which they help to relieve pain [14]; however, this  
therapy remains controversial, has not been consistently supported in studies and is most likely to benefit women 
and those with mild disease.  Steroid therapy has been shown to dramatically improve symptoms in patients 
with autoimmune pancreatitis [15]. 
Many anecdotal reports, including our own, have documented significant improvement in clinical symptoms 
with the use of pancreatic enzyme supplementation and either H2 blockers or proton pump inhibitors; pancreatic 
enzyme supplementation is devoid of major side effects although, very rarely, allergic reactions have been re-
ported.  Colonic stricture is a rare complication of pancreatic enzyme therapy in patients with cystic fibrosis [16]. 
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Rise  According to clinical trials, pancreatic enzyme supplements are most likely to relieve pain in patients with small 
duct disease [17].  Treatment with octreotide, a potent pancreatic enzyme secretion inhibitor, is not widely recom-
mended.  The use of antioxidants has shown some benefit but further studies are warranted.  CCK receptor an-
tagonists (MK329) and the treatment of pain with tricyclic antidepressants and gabapentin are other promising 
options [17].  Endoscopic ductal dilatation, in patients with mild pancreatitis, and endoscopic ultrasound or CT 
guided celiac plexus blockade are other modalities being used for the relief of chronic pain.  Finally, surgery is 
reserved for the management of intractable pain. 
 
Conclusion:  The accurate diagnosis of chronic pancreatitis relies on a constellation of imaging and laboratory 
studies.  When such studies are unavailable or contraindicated (e.g. the presence of acute renal failure), a thera-
peutic and diagnostic trial of pancreatic enzyme supplementation may be warranted; indeed, in our patient, this 
therapy completely controlled his symptoms and protected him from the potential complications of dehydration 
and electrolyte imbalance.  When the clinical suspicion of chronic pancreatitis is high and the resources are lim-
ited, this intervention may prove to be an excellent strategy. 
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